Novartis Ag (NVSEF) Liabilities and Shareholders Equity (2009 - 2025)

Novartis Ag has disclosed Liabilities and Shareholders Equity across 12 years of filings, most recently posting $110.9 billion for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $110.9 billion, up 8.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $215.3 billion (up 7.81% YoY), and the FY2025 annual result was $110.9 billion, up 8.51% from the prior year.
• Liabilities and Shareholders Equity came in at $110.9 billion for Q4 2025 at Novartis Ag, up from $104.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $131.8 billion in Q4 2021 to a low of $97.5 billion in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $111.0 billion (2023), against an average of $112.2 billion.
• Across the five-year window, Liabilities and Shareholders Equity fell 14.91% in 2023 and gained 8.51% in 2025, its largest moves.
• Novartis Ag's Liabilities and Shareholders Equity stood at $131.8 billion in 2021, then declined by 10.88% to $117.5 billion in 2022, then declined by 14.91% to $99.9 billion in 2023, then advanced by 2.3% to $102.2 billion in 2024, then rose by 8.51% to $110.9 billion in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $110.9 billion (Q4 2025), $104.4 billion (Q2 2025), and $102.2 billion (Q4 2024), per Business Quant data.